财报数据
| EPS 实际 | $2.7 |
| EPS 预期 | $2.6914 |
| EPS 超预期 % | +0.32% |
| 收入实际 | $24,062,000,000 |
| 收入预期 | $23,865,847,398 |
| 判据命中 | 数值 A 新闻 B |
观察状态
| 状态 | 🟢 已收尾 |
| Time0（观察起点） | 2026-04-14 14:13:00 UTC （盘中） |
| 基准价 P₀ | $239.98 |
| 累计最高价 | $240.69 |
| 峰值涨幅 | +0.30% |
| Time1（回撤触发） | 2026-04-14 14:25:00 UTC |
| Time1 价格 | $238.20 |
| 最终涨幅 | -0.74% |
分钟级价格（Massive 数据） 绿线 = Time0 发生时刻 · 红线 = Time1 回撤触发时刻
加载中…
触发新闻（1 条）
按发布时间升序；最早一篇的 published_utc 即为 Time0
2026-04-14 14:13:44 UTC
· Benzinga
·
✓ LLM 判定为 beat
（置信 0.98）
Johnson & Johnson reported Q1 2025 adjusted earnings of $2.70 per share, beating consensus, with sales of $24.06 billion up 9.9% YoY. Cancer drug revenue surged 22.8%, driven by oncology and neuroscie…
└ LLM 理由: The article says Johnson & Johnson reported Q1 2025 adjusted earnings of $2.70 per share, explicitly 'beating consensus,' which indicates the just-reported earnings exceeded analyst expectations.